Zoledronic Acid Disodium Salt Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bisphosphonate compounds, such as zoledronic acid, have low oral bioavailability, limiting their effectiveness in treating bone-related and cancer-related conditions, and existing dosage forms do not adequately address pain relief for conditions like osteoporosis, Paget's disease, and complex regional pain syndrome.
Innovation Solution
Administering zoledronic acid in the disodium salt form, which enhances bioavailability and allows for a lower molar amount to achieve comparable plasma levels, providing effective pain relief for conditions like osteoporosis, Paget's disease, and complex regional pain syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If zoledronic acid is administered in the diacid form, then the dosage form is stable and easy to manufacture, but the oral bioavailability is low
Solution Approach 1:
The patent changes the chemical form of zoledronic acid from diacid form to disodium salt form, which fundamentally alters the bioavailability parameter while maintaining manufacturing feasibility. This parameter change enables effective oral administration by improving absorption without requiring complex formulation modifications.
2Reliability
If higher molar amounts of zoledronic acid are used to compensate for low bioavailability, then plasma levels can be achieved, but the dosage requirements increase and side effects may increase
Solution Approach 1:
By changing the salt form from diacid to disodium salt, the patent improves the bioavailability parameter, which allows achieving target plasma concentrations with lower molar amounts of the drug. This reduces the quantity of substance required while maintaining therapeutic effectiveness and potentially reducing dose-related side effects.
3Ease of operation
If oral dosage forms are used for bisphosphonates, then patient compliance improves, but the bioavailability remains insufficient for effective treatment
Solution Approach 1:
The patent modifies the chemical parameter of zoledronic acid by using the disodium salt form, which significantly improves oral bioavailability. This enables oral dosage forms to achieve sufficient plasma concentrations for effective treatment, thereby maintaining patient compliance advantages while resolving the bioavailability insufficiency problem.
Data Source
AI summary
Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as treating pain associated with Paget's disease of bone.